Market Overview

UPDATE: Piper Jaffray Downgrades Endo Health Solutions to Neutral, Lowers PT

Share:
Related ENDP
Benzinga's M&A Chatter for Monday March 16, 2015
Morning Market Gainers
Mylan Is One Of The Most Undervalued Generic Companies (Seeking Alpha)

In a report published Friday, Piper Jaffray & Co. downgraded its rating on Endo Health Solutions (NASDAQ: ENDP) from Overweight to Neutral, and lowered its price target from $37.00 to $28.00.

Piper Jaffray noted, “We are downgrading Endo to a Neutral from an Overweight and lowering our price target to $28 from $37. Endo's tempered 2013 guidance reflects only limited Opana ER generic competition, and given the absence of FDA action on the legacy formulation, we believe there is considerable risk to the new diluted EPS range of $4.40 to $4.70. We estimate that 2014 EPS, factoring a major Opana ER erosion, would be close to $3.50. Though this implies a P/E of only 7.5x, a deeper EPS trough longer-term looks even more likely given the gradual but inexorable decline of Lidoderm. Given the uncertainty on Opana ER, not to mention underperformance of the AMS device business, we find it difficult to envision substantial value creation as 2013 progresses.”

Endo Health Solutions closed on Thursday at $26.25.

Latest Ratings for ENDP

DateFirmActionFromTo
Mar 2015Morgan StanleyReinstatesOverweight
Mar 2015Canaccord GenuityMaintainsBuy
Mar 2015Keefe Bruyette & WoodsMaintainsOutperform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Downgrades Analyst Ratings

 

Related Articles (ENDP)

Around the Web, We're Loving...